Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
No relapses occurred in patients who achieved early MRD negativity per the next-generation sequencing MRD assay.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
The efficacy of CNS prophylaxis with intrathecal chemotherapy in Ph+ ALL depends upon how many times it is given.
Ponatinib plus hyper-CVAD led to "excellent" outcomes in patients with newly diagnosed Ph+ ALL.
Advertisement
A chemotherapy-free regimen with ponatinib and blinatumomab led to high complete molecular response rates in Ph+ ALL.
A chemotherapy-free regimen led to high rates of complete remission and MRD negativity in patients with Ph+ ALL.
Inotuzumab ozogamicin plus hyper-CVAD with sequential blinatumomab is safe and effective for Ph-negative B-cell ALL.
Adding blinatumomab to consolidation chemotherapy led to improved survival in MRD-negative patients with B-lineage ALL.
Although the utility of MRD in ALL has been well defined over the last decades, several questions remain.
Patients with ALL who underwent allogeneic HSCT in their first complete remission had a two-year OS rate of 73.9%.
An asparaginase-containing, pediatric-inspired regimen led to an overall survival benefit in teens and young adults with ALL.
Amy Kirkwood, MSc, discusses results from the randomized phase III UKALL trial during the 2022 ASH Annual Meeting.
There has been an improvement in the prognosis of older patients diagnosed with acute lymphoblastic leukemia.
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
In the inaugural episode of The HemOnc Pulse, Chadi Nabhan, MD, MBA, FACP, hosts Hagop Kantarjian, MD, and Elias Jabbour, MD.
Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about ALL treatment advances at ASH 2022.
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726